For millions of people worldwide, osteoarthritis is a source of relentless, progressive physical decline. Characterized by persistent pain, swelling, and reduced mobility, the condition turns once-simple daily activities—such as walking, climbing stairs, or grasping household objects—into significant hurdles. While the medical community has long relied on a combination of over-the-counter anti-inflammatory drugs, physical therapy, and steroid injections to manage the symptoms of the disease, these treatments share a common, critical limitation: they address the superficial experience of pain without halting the underlying mechanical and biological deterioration of the joint.
Now, a groundbreaking study led by researchers at Yale University offers a compelling new direction for treatment. Published in the journal Bioactive Materials, the research indicates that lacosamide—a medication currently approved for the treatment of epilepsy—may hold the key to a dual-purpose therapeutic strategy. By inhibiting a specific protein involved in both pain signaling and cartilage degradation, the drug has shown the ability to not only alleviate discomfort but also actively support the repair of damaged joint tissue. These effects were found to be most profound when the drug was delivered directly into the joint via a novel, temperature-responsive hydrogel.
The Biological Mechanism of Osteoarthritis
To understand the significance of this discovery, one must first look beyond the common characterization of osteoarthritis as mere "wear and tear." While the term implies a simple mechanical breakdown over time, the reality is a complex biological imbalance occurring at the cellular level.
Within a healthy joint, the cartilage is maintained by specialized cells known as chondrocytes. These cells act as custodians, continuously balancing the creation of new extracellular matrix proteins with the removal of degraded, older material. In an osteoarthritic joint, this delicate equilibrium is shattered. The rate at which cartilage breaks down begins to outpace the rate of renewal, leading to a thinning of the protective cushion between bones. As the cartilage wears away, the bones eventually rub against one another, causing friction, inflammation, and chronic pain. In advanced stages of the disease, this structural failure often leaves patients with few options other than invasive joint reconstruction, such as total knee replacement surgery.
"There is a major unmet need in osteoarthritis," says Chuan-Ju Liu, PhD, the study’s principal investigator and Charles W. Ohse Professor of Orthopaedics & Rehabilitation at Yale. "We need therapies that don’t just mask pain but actually change how the disease progresses." Currently, no medication approved by the U.S. Food and Drug Administration (FDA) is capable of simultaneously quelling the pain of osteoarthritis and preventing the structural breakdown of cartilage. The work led by Liu suggests that a single, targeted approach might soon bridge this gap, offering patients a way to preserve joint integrity while managing their symptoms without the risks associated with long-term opioid use.
A Protein Linked to Pain and Cartilage Loss
The Yale team’s breakthrough centers on the protein Nav1.7, which functions as a voltage-gated sodium channel. In the human body, these channels serve as microscopic gates within cell membranes, facilitating the electrical signaling necessary for nerve function. For years, the scientific consensus held that Nav1.7 was primarily active within specialized sensory neurons that transmit pain signals from the periphery to the brain. However, recent investigations by Liu and his research team have revealed that this protein plays a much more pervasive role than previously understood, appearing in high concentrations within chondrocytes—the very cells responsible for the health of cartilage.
In a healthy joint, Nav1.7 activity is minimal. However, in the context of osteoarthritis, the expression and activity of this protein increase substantially. The researchers discovered that this hyper-activity serves two destructive purposes: it intensifies pain signaling and simultaneously coerces chondrocytes into a state that promotes cartilage degradation rather than repair. This dual role makes Nav1.7 an unusually potent therapeutic target. By effectively blocking this single protein, scientists believe they can calm the nerves that report pain while signaling the cartilage cells to halt their destructive processes and initiate a regenerative phase.
"When Nav1.7 becomes dysregulated, it contributes to both joint degeneration and pain," explains Liu. "Our findings suggest that Nav1.7 is a dual-acting target. By blocking this single protein, we can potentially quiet the pain nerves and tell the cartilage cells to not only stop breaking down but start repairing as well."
Epilepsy Drug Shows Potential for Cartilage Repair
Rather than embarking on the lengthy and costly process of developing a brand-new chemical compound, the researchers elected to screen existing drugs that act as sodium channel inhibitors. Among those tested, lacosamide emerged as the most promising candidate. Not only did it demonstrate strong biological efficacy at relatively low concentrations, but it also offered a superior safety profile compared to older, more toxic drugs within the same class.
However, the team discovered that the drug’s effectiveness is highly dependent on precision. Their findings suggest that the biological system in the joint is finely tuned; when it comes to lacosamide, "more" is not necessarily "better." At an optimal, low concentration, the drug effectively encouraged chondrocytes to produce the proteins necessary for building new cartilage while suppressing the enzymes that facilitate tissue degradation. If the concentration was too high or too low, these beneficial effects began to wane.
"This tells us the system is finely tuned," Liu notes. "There is an optimal range where the drug helps restore balance without overcorrecting. What stood out was not just its effectiveness, but how little of a dose was needed."
Further analysis revealed that lacosamide’s impact extends to cellular communication. The drug stimulated the release of two vital signaling proteins: HSP70 and midkine. HSP70 is well-regarded for its role in helping cells navigate stress and facilitating tissue repair, while midkine acts as a regulator of inflammation, shielding the joint from the destructive effects of chronic degeneration. Together, these proteins foster a microenvironment that is conducive to the long-term maintenance of healthy cartilage.
Smart Hydrogel Keeps the Drug Inside the Joint
While oral administration of lacosamide proved effective in initial preclinical testing, the researchers recognized that systemic delivery—in which a drug circulates through the entire body—could lead to unwanted off-target effects. To maximize safety and efficacy, the team explored intra-articular injection, which delivers the medication directly into the site of the injury.
However, they faced a significant engineering challenge. "The knee joint, which is also the most common location for osteoarthritis, naturally acts like a leaky bucket," says Liu. "The body’s drainage system can clear out liquids injected into the knee within hours."
To solve this, the team developed a specialized, biocompatible hydrogel made from Collagen II. This "smart" material is temperature-responsive; it remains in a liquid state while kept at cool temperatures in a syringe, but transitions into a firm, jelly-like consistency the moment it is injected and reaches body temperature. Once inside the joint, the hydrogel serves as a sustained-release reservoir for the lacosamide. It holds the drug in the precise area where it is needed most, releasing it slowly over the course of several weeks.
This mechanism effectively transforms a treatment that might otherwise require daily oral dosing into a long-lasting, localized intervention. In preclinical studies, a single injection of the lacosamide-loaded hydrogel administered every four weeks proved more effective at preventing cartilage loss than daily oral doses of the medication.
Moving Toward Clinical Application
The fact that lacosamide is already FDA-approved for epilepsy provides a massive advantage for the transition to human clinical trials. Because the drug’s safety profile is already well-documented, the researchers can move toward testing its efficacy in osteoarthritis patients much more rapidly than would be possible with a completely novel therapeutic agent. Furthermore, because lacosamide has been previously studied in human subjects dealing with specific nerve-related pain conditions linked to Nav1.7 mutations, the researchers have a strong basis for believing that the benefits observed in the laboratory will translate into tangible clinical outcomes for patients.
This research represents a broader, emerging trend in modern medicine: the integration of existing pharmaceuticals with advanced biomaterials to gain granular control over how and where a treatment is delivered. If this approach proves successful in human clinical trials, it could fundamentally alter the management of osteoarthritis. By reducing the frequency of medical procedures, minimizing systemic side effects, and offering genuine protection against the structural deterioration of joints, this system could offer millions of patients a path away from the chronic, life-altering pain of degenerative disease.
"We are not just developing a treatment," concludes Liu. "We are developing a system that allows the medicine to work more effectively where it matters most. Our goal is to move beyond symptom control and towards true disease modification. This effort brings us closer to that reality."
